{"transactions":[{"id":710103,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-14T20:18:54.000Z","date":"2026-07-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":14041,"price":4.26,"value":59814.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":198417,"source":{"system":"sec-edgar","filing":"0001104659-26-083516","document":"tm2620483-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926083516/tm2620483-1_4seq1.xml","form_type":"4"}},{"id":799284,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51083,"kind":"person","name":"Gilmer Daniel B.","position":1,"cik":"0002122703","reported_name":"Gilmer Daniel B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-04-28T20:24:35.000Z","date":"2026-04-24","kind":"grant","planned":false,"acquired":true,"shares":51280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests as to one-third of the underlying shares of common stock on each of the first, second and third annual anniversaries of the date of grant, subject to continuous service through the vesting date."}],"balance_after":51280,"derivative":{"exercise_price":12.92,"expiration_date":"2036-04-24","underlying":"Common Stock","underlying_shares":51280},"source":{"system":"sec-edgar","filing":"0001104659-26-050391","document":"tm2612896-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926050391/tm2612896-2_4seq1.xml","form_type":"4"}},{"id":839634,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":60242,"kind":"person","name":"Kyme Pierre","position":1,"cik":"0002028892","reported_name":"Kyme Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-03-17T23:48:27.000Z","date":"2026-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1030,"price":10.54,"value":10856.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":9461,"source":{"system":"sec-edgar","filing":"0001104659-26-029712","document":"tm269075-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926029712/tm269075-2_4seq1.xml","form_type":"4"}},{"id":839633,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-17T23:46:39.000Z","date":"2026-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":4919,"price":10.54,"value":51846.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":212458,"source":{"system":"sec-edgar","filing":"0001104659-26-029711","document":"tm269075-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926029711/tm269075-1_4seq1.xml","form_type":"4"}},{"id":849507,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61588,"kind":"person","name":"Kramer Robin","position":1,"cik":"0001609222","reported_name":"Kramer Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:18:25.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":25640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date."}],"balance_after":25640,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":25640},"source":{"system":"sec-edgar","filing":"0001104659-26-026589","document":"tm268588-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026589/tm268588-5_4seq1.xml","form_type":"4"}},{"id":849505,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":60242,"kind":"person","name":"Kyme Pierre","position":1,"cik":"0002028892","reported_name":"Kyme Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:18:19.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":183142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date."}],"balance_after":183142,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":183142},"source":{"system":"sec-edgar","filing":"0001104659-26-026588","document":"tm268588-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026588/tm268588-9_4seq1.xml","form_type":"4"}},{"id":849503,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61586,"kind":"person","name":"House David Duane","position":1,"cik":"0002034219","reported_name":"House David Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance, and PFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:17:29.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":109885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date."}],"balance_after":109885,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":109885},"source":{"system":"sec-edgar","filing":"0001104659-26-026587","document":"tm268588-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026587/tm268588-8_4seq1.xml","form_type":"4"}},{"id":849504,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61587,"kind":"person","name":"PATTI JOSEPH M","position":1,"cik":"0001283215","reported_name":"PATTI JOSEPH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:17:22.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":25640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date."}],"balance_after":25640,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":25640},"source":{"system":"sec-edgar","filing":"0001104659-26-026586","document":"tm268588-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026586/tm268588-4_4seq1.xml","form_type":"4"}},{"id":849502,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61585,"kind":"person","name":"Peterson Todd C.","position":1,"cik":"0001791061","reported_name":"Peterson Todd C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:16:07.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":25640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date."}],"balance_after":25640,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":25640},"source":{"system":"sec-edgar","filing":"0001104659-26-026585","document":"tm268588-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026585/tm268588-3_4seq1.xml","form_type":"4"}},{"id":849501,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51851,"kind":"person","name":"Odysseas Kostas D","position":1,"cik":"0001483080","reported_name":"Odysseas Kostas D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:15:47.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":25640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date."}],"balance_after":25640,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":25640},"source":{"system":"sec-edgar","filing":"0001104659-26-026583","document":"tm268588-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026583/tm268588-6_4seq1.xml","form_type":"4"}},{"id":849500,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:15:03.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":421226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date."}],"balance_after":421226,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":421226},"source":{"system":"sec-edgar","filing":"0001104659-26-026582","document":"tm268588-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026582/tm268588-7_4seq1.xml","form_type":"4"}},{"id":849499,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49455,"kind":"person","name":"Schlesinger Sarah J.","position":1,"cik":"0001579873","reported_name":"Schlesinger Sarah J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:14:59.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":25640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date."}],"balance_after":25640,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":25640},"source":{"system":"sec-edgar","filing":"0001104659-26-026581","document":"tm268588-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026581/tm268588-2_4seq1.xml","form_type":"4"}},{"id":849498,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49454,"kind":"person","name":"Haimovitz Jules","position":1,"cik":"0001340855","reported_name":"Haimovitz Jules","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:13:28.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":25640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date."}],"balance_after":25640,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":25640},"source":{"system":"sec-edgar","filing":"0001104659-26-026579","document":"tm268588-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026579/tm268588-1_4seq1.xml","form_type":"4"}},{"id":1088220,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-14T20:05:21.000Z","date":"2025-07-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":13637,"price":2.27,"value":30955.99,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":217377,"source":{"system":"sec-edgar","filing":"0001104659-25-067746","document":"tm2520709-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925067746/tm2520709-1_4seq1.xml","form_type":"4"}},{"id":1165971,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-25T20:07:12.000Z","date":"2025-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":6061,"price":1.95,"value":11818.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":231014,"source":{"system":"sec-edgar","filing":"0001104659-25-039417","document":"tm2513168-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925039417/tm2513168-3_4seq1.xml","form_type":"4"}},{"id":1165970,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-25T20:07:12.000Z","date":"2024-07-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":22925,"price":2.68,"value":61439.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":237075,"source":{"system":"sec-edgar","filing":"0001104659-25-039417","document":"tm2513168-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925039417/tm2513168-3_4seq1.xml","form_type":"4"}},{"id":1165972,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":60242,"kind":"person","name":"Kyme Pierre","position":1,"cik":"0002028892","reported_name":"Kyme Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-04-25T20:06:15.000Z","date":"2025-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1027,"price":1.95,"value":2002.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":10491,"source":{"system":"sec-edgar","filing":"0001104659-25-039414","document":"tm2513168-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925039414/tm2513168-2_4seq1.xml","form_type":"4"}},{"id":1279285,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51851,"kind":"person","name":"Odysseas Kostas D","position":1,"cik":"0001483080","reported_name":"Odysseas Kostas D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:22:54.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date."}],"balance_after":54343,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-25-010568","document":"tm255864-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010568/tm255864-9_4seq1.xml","form_type":"4"}},{"id":1279283,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49455,"kind":"person","name":"Schlesinger Sarah J.","position":1,"cik":"0001579873","reported_name":"Schlesinger Sarah J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:21:40.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date."}],"balance_after":54343,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-25-010567","document":"tm255864-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010567/tm255864-8_4seq1.xml","form_type":"4"}},{"id":1279284,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61585,"kind":"person","name":"Peterson Todd C.","position":1,"cik":"0001791061","reported_name":"Peterson Todd C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:20:56.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date."}],"balance_after":54343,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-25-010566","document":"tm255864-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010566/tm255864-7_4seq1.xml","form_type":"4"}},{"id":1279282,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61587,"kind":"person","name":"PATTI JOSEPH M","position":1,"cik":"0001283215","reported_name":"PATTI JOSEPH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:20:10.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date."}],"balance_after":54343,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-25-010564","document":"tm255864-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010564/tm255864-6_4seq1.xml","form_type":"4"}},{"id":1279281,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":60242,"kind":"person","name":"Kyme Pierre","position":1,"cik":"0002028892","reported_name":"Kyme Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:19:28.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on February 5th of each of 2026, 2027, 2028 and 2029, in each case subject to continuous service through the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-25-010561","document":"tm255864-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010561/tm255864-5_4seq1.xml","form_type":"4"}},{"id":1279280,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61588,"kind":"person","name":"Kramer Robin","position":1,"cik":"0001609222","reported_name":"Kramer Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:18:05.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date."}],"balance_after":54343,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-25-010558","document":"tm255864-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010558/tm255864-4_4seq1.xml","form_type":"4"}},{"id":1279278,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61586,"kind":"person","name":"House David Duane","position":1,"cik":"0002034219","reported_name":"House David Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance, and PFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:17:04.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on February 5th of each of 2026, 2027, 2028 and 2029, in each case subject to continuous service through the applicable vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-25-010556","document":"tm255864-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010556/tm255864-3_4seq1.xml","form_type":"4"}},{"id":1279279,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49454,"kind":"person","name":"Haimovitz Jules","position":1,"cik":"0001340855","reported_name":"Haimovitz Jules","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:16:04.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date."}],"balance_after":54343,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-25-010553","document":"tm255864-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010553/tm255864-2_4seq1.xml","form_type":"4"}},{"id":1279277,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:15:15.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on February 5th of each of 2026, 2027, 2028, and 2029, in each case subject to continuous service through the applicable vesting date."}],"balance_after":240000,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001104659-25-010550","document":"tm255864-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010550/tm255864-1_4seq1.xml","form_type":"4"}},{"id":1392740,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61586,"kind":"person","name":"House David Duane","position":1,"cik":"0002034219","reported_name":"House David Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance, and PFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-10-03T20:15:12.000Z","date":"2024-10-02","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest and become exercisable 25% on August 16th of each of 2025, 2026, 2027, and 2028, in each case subject to continuous service through the applicable vesting date."}],"balance_after":75000,"derivative":{"exercise_price":2.32,"expiration_date":"2034-10-02","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-24-105848","document":"tm2425499-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924105848/tm2425499-2_4seq1.xml","form_type":"4"}},{"id":1573490,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61587,"kind":"person","name":"PATTI JOSEPH M","position":1,"cik":"0001283215","reported_name":"PATTI JOSEPH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:05:15.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date."}],"balance_after":94009,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-24-035732","document":"tm249071-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035732/tm249071-4_4seq1.xml","form_type":"4"}},{"id":1573489,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61587,"kind":"person","name":"PATTI JOSEPH M","position":1,"cik":"0001283215","reported_name":"PATTI JOSEPH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:05:15.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":39666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024."}],"balance_after":39666,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":39666},"source":{"system":"sec-edgar","filing":"0001104659-24-035732","document":"tm249071-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035732/tm249071-4_4seq1.xml","form_type":"4"}},{"id":1573488,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61588,"kind":"person","name":"Kramer Robin","position":1,"cik":"0001609222","reported_name":"Kramer Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:03:33.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date."}],"balance_after":94009,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-24-035730","document":"tm249071-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035730/tm249071-3_4seq1.xml","form_type":"4"}},{"id":1573487,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61588,"kind":"person","name":"Kramer Robin","position":1,"cik":"0001609222","reported_name":"Kramer Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:03:33.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":39666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024."}],"balance_after":39666,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":39666},"source":{"system":"sec-edgar","filing":"0001104659-24-035730","document":"tm249071-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035730/tm249071-3_4seq1.xml","form_type":"4"}},{"id":1573486,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61585,"kind":"person","name":"Peterson Todd C.","position":1,"cik":"0001791061","reported_name":"Peterson Todd C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:03:18.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date."}],"balance_after":94009,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-24-035729","document":"tm249071-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035729/tm249071-8_4seq1.xml","form_type":"4"}},{"id":1573485,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61585,"kind":"person","name":"Peterson Todd C.","position":1,"cik":"0001791061","reported_name":"Peterson Todd C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:03:18.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":39666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024."}],"balance_after":39666,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":39666},"source":{"system":"sec-edgar","filing":"0001104659-24-035729","document":"tm249071-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035729/tm249071-8_4seq1.xml","form_type":"4"}},{"id":1573484,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":92975,"kind":"person","name":"Rychlik Richard","position":1,"cik":"0001994635","reported_name":"Rychlik Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller and PFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:02:52.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on March 14th of each of 2025, 2026, 2027, and 2028."}],"balance_after":40000,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-24-035728","document":"tm249071-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035728/tm249071-7_4seq1.xml","form_type":"4"}},{"id":1573483,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":92975,"kind":"person","name":"Rychlik Richard","position":1,"cik":"0001994635","reported_name":"Rychlik Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller and PFO"}}],"security":"Common Stock","published_at":"2024-03-19T00:02:52.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001104659-24-035728","document":"tm249071-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035728/tm249071-7_4seq1.xml","form_type":"4"}},{"id":1573482,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49455,"kind":"person","name":"Schlesinger Sarah J.","position":1,"cik":"0001579873","reported_name":"Schlesinger Sarah J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:02:22.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date."}],"balance_after":94009,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-24-035727","document":"tm249071-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035727/tm249071-6_4seq1.xml","form_type":"4"}},{"id":1573481,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49455,"kind":"person","name":"Schlesinger Sarah J.","position":1,"cik":"0001579873","reported_name":"Schlesinger Sarah J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:02:22.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":39666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024."}],"balance_after":39666,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":39666},"source":{"system":"sec-edgar","filing":"0001104659-24-035727","document":"tm249071-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035727/tm249071-6_4seq1.xml","form_type":"4"}},{"id":1573480,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49454,"kind":"person","name":"Haimovitz Jules","position":1,"cik":"0001340855","reported_name":"Haimovitz Jules","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:01:28.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date."}],"balance_after":94009,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-24-035726","document":"tm249071-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035726/tm249071-2_4seq1.xml","form_type":"4"}},{"id":1573479,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49454,"kind":"person","name":"Haimovitz Jules","position":1,"cik":"0001340855","reported_name":"Haimovitz Jules","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:01:28.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":39666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024."}],"balance_after":39666,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":39666},"source":{"system":"sec-edgar","filing":"0001104659-24-035726","document":"tm249071-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035726/tm249071-2_4seq1.xml","form_type":"4"}},{"id":1573478,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51851,"kind":"person","name":"Odysseas Kostas D","position":1,"cik":"0001483080","reported_name":"Odysseas Kostas D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:00:26.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":54343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date."}],"balance_after":94009,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":54343},"source":{"system":"sec-edgar","filing":"0001104659-24-035724","document":"tm249071-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035724/tm249071-5_4seq1.xml","form_type":"4"}},{"id":1573477,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51851,"kind":"person","name":"Odysseas Kostas D","position":1,"cik":"0001483080","reported_name":"Odysseas Kostas D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:00:26.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":39666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024."}],"balance_after":39666,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":39666},"source":{"system":"sec-edgar","filing":"0001104659-24-035724","document":"tm249071-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035724/tm249071-5_4seq1.xml","form_type":"4"}},{"id":1573476,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-19T00:00:18.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on March 14th of each of 2025, 2026, 2027, and 2028."}],"balance_after":240000,"derivative":{"exercise_price":3.38,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001104659-24-035723","document":"tm249071-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035723/tm249071-1_4seq1.xml","form_type":"4"}},{"id":1573475,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-19T00:00:18.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":260000,"source":{"system":"sec-edgar","filing":"0001104659-24-035723","document":"tm249071-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924035723/tm249071-1_4seq1.xml","form_type":"4"}},{"id":1700437,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49455,"kind":"person","name":"Schlesinger Sarah J.","position":1,"cik":"0001579873","reported_name":"Schlesinger Sarah J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-27T02:55:39.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":10461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests immediately prior to the Company's 2024 annual shareholders meeting."}],"balance_after":10461,"derivative":{"exercise_price":2.39,"expiration_date":"2033-12-21","underlying":"Common Stock","underlying_shares":10461},"source":{"system":"sec-edgar","filing":"0001104659-23-129371","document":"tm2333426-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923129371/tm2333426-4_4seq1.xml","form_type":"4"}},{"id":1700431,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61585,"kind":"person","name":"Peterson Todd C.","position":1,"cik":"0001791061","reported_name":"Peterson Todd C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-27T02:55:01.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":10461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests immediately prior to the Company's 2024 annual shareholders meeting."}],"balance_after":10461,"derivative":{"exercise_price":2.39,"expiration_date":"2033-12-21","underlying":"Common Stock","underlying_shares":10461},"source":{"system":"sec-edgar","filing":"0001104659-23-129370","document":"tm2333426-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923129370/tm2333426-3_4seq1.xml","form_type":"4"}},{"id":1700430,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61588,"kind":"person","name":"Kramer Robin","position":1,"cik":"0001609222","reported_name":"Kramer Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-27T02:54:48.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":10461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests immediately prior to the Company's 2024 annual shareholders meeting."}],"balance_after":10461,"derivative":{"exercise_price":2.39,"expiration_date":"2033-12-21","underlying":"Common Stock","underlying_shares":10461},"source":{"system":"sec-edgar","filing":"0001104659-23-129369","document":"tm2333426-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923129369/tm2333426-6_4seq1.xml","form_type":"4"}},{"id":1700429,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61587,"kind":"person","name":"PATTI JOSEPH M","position":1,"cik":"0001283215","reported_name":"PATTI JOSEPH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-27T02:54:29.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":10461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests immediately prior to the Company's 2024 annual shareholders meeting."}],"balance_after":10461,"derivative":{"exercise_price":2.39,"expiration_date":"2033-12-21","underlying":"Common Stock","underlying_shares":10461},"source":{"system":"sec-edgar","filing":"0001104659-23-129368","document":"tm2333426-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923129368/tm2333426-2_4seq1.xml","form_type":"4"}},{"id":1700428,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":92975,"kind":"person","name":"Rychlik Richard","position":1,"cik":"0001994635","reported_name":"Rychlik Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller and PFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-27T02:54:25.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest in equal annual installments on each of the first four anniversaries of September 5, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Option shall vest in equal annual installments on each of the first four anniversaries of September 5, 2023."}],"balance_after":50000,"derivative":{"exercise_price":2.39,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-23-129367","document":"tm2333426-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923129367/tm2333426-8_4seq1.xml","form_type":"4"}},{"id":1700427,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49454,"kind":"person","name":"Haimovitz Jules","position":1,"cik":"0001340855","reported_name":"Haimovitz Jules","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-27T02:53:36.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":10461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests immediately prior to the Company's 2024 annual shareholders meeting."}],"balance_after":10461,"derivative":{"exercise_price":2.39,"expiration_date":"2033-12-21","underlying":"Common Stock","underlying_shares":10461},"source":{"system":"sec-edgar","filing":"0001104659-23-129366","document":"tm2333426-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923129366/tm2333426-5_4seq1.xml","form_type":"4"}},{"id":1700426,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-27T02:53:29.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on July 10th of each of 2024, 2025, 2026, and 2027."}],"balance_after":200000,"derivative":{"exercise_price":2.39,"expiration_date":"2033-12-21","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-23-129365","document":"tm2333426-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923129365/tm2333426-7_4seq1.xml","form_type":"4"}},{"id":1700425,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":30633,"kind":"person","name":"Birx Deborah","position":1,"cik":"0001849673","reported_name":"Birx Deborah","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-27T02:53:29.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001104659-23-129365","document":"tm2333426-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923129365/tm2333426-7_4seq1.xml","form_type":"4"}},{"id":1700424,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51851,"kind":"person","name":"Odysseas Kostas D","position":1,"cik":"0001483080","reported_name":"Odysseas Kostas D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-27T02:53:27.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":10461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests immediately prior to the Company's 2024 annual shareholders meeting."}],"balance_after":10461,"derivative":{"exercise_price":2.39,"expiration_date":"2033-12-21","underlying":"Common Stock","underlying_shares":10461},"source":{"system":"sec-edgar","filing":"0001104659-23-129364","document":"tm2333426-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923129364/tm2333426-1_4seq1.xml","form_type":"4"}},{"id":2055968,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Debt convertible into Common Stock","published_at":"2023-01-13T02:21:20.000Z","date":"2023-01-10","kind":"purchase","acquired":true,"price":30000000,"reported_value":30000000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"security","element":"securityTitle","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"security","element":"securityTitle","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"security","element":"securityTitle","label":"F5","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. In 2021, Innoviva designated Jules Haimovitz, a member of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, as a result of or in connection with the transactions reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As previously disclosed on Amendment No. 8 to Statement of Beneficial Ownership on Schedule 13D, as filed by Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\") with the Securities and Exchange Commission (\"Commission\") on January 10, 2023, Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") entered into, as borrower, a secured convertible credit and security agreement (the \"Credit Agreement\") with Innoviva Sub on January 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30,000,000 (the \"Loan\") at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Loan shall be converted (the \"Mandatory Conversion\") into shares of the Issuer's common stock, $0.01 par value per share (\"Common Stock\") at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Credit Agreement also requires the Issuer to file a registration statement (the \"Registration Statement\") for the resale of all securities issued to Innoviva Sub in connection with any conversion under the Credit Agreement. After the Registration Statement has been declared effective by the Commission, any outstanding Loan amount, including all accrued and unpaid interest thereon, may be converted at Innoviva Sub's option into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Credit Agreement, which is $1.52 (as may be appropriately adjusted for any stock split, combination or similar act) (the \"Optional Conversion\"). As of January 10, 2023, pursuant to the Optional Conversion, the Loan is convertible into 19,736,843 shares of Common Stock of the Issuer, contingent upon the effectiveness of the Registration Statement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of 16,365,969 shares of Common Stock, 4,500,000 warrants to purchase Common Stock with an exercise price of $5.00, and 6,153,847 warrants to purchase Common Stock with an exercise price of $3.25 and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. In 2021, Innoviva designated Jules Haimovitz, a member of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, as a result of or in connection with the transactions reported on this Form 4."}],"derivative":{"exercise_price":1.52,"underlying":"Common Stock","underlying_shares":19736843},"source":{"system":"sec-edgar","filing":"0001104659-23-003540","document":"tm232524-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923003540/tm232524-2_4seq1.xml","form_type":"4"}},{"id":2296623,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61585,"kind":"person","name":"Peterson Todd C.","position":1,"cik":"0001791061","reported_name":"Peterson Todd C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-15T19:56:56.000Z","date":"2022-04-13","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":33000,"derivative":{"exercise_price":5.11,"expiration_date":"2032-04-13","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-22-046459","document":"tm2212851-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922046459/tm2212851-9_4seq1.xml","form_type":"4"}},{"id":2296621,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128027,"kind":"person","name":"Patrick Todd","position":1,"cik":"0001762285","reported_name":"Patrick Todd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-15T19:55:45.000Z","date":"2022-04-13","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":33000,"derivative":{"exercise_price":5.11,"expiration_date":"2032-04-13","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-22-046455","document":"tm2212851-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922046455/tm2212851-8_4seq1.xml","form_type":"4"}},{"id":2296620,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49455,"kind":"person","name":"Schlesinger Sarah J.","position":1,"cik":"0001579873","reported_name":"Schlesinger Sarah J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-15T19:54:50.000Z","date":"2022-04-13","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":33000,"derivative":{"exercise_price":5.11,"expiration_date":"2032-04-13","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-22-046453","document":"tm2212851-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922046453/tm2212851-7_4seq1.xml","form_type":"4"}},{"id":2296622,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61588,"kind":"person","name":"Kramer Robin","position":1,"cik":"0001609222","reported_name":"Kramer Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-15T19:53:15.000Z","date":"2022-04-13","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant."}],"balance_after":33000,"derivative":{"exercise_price":5.11,"expiration_date":"2032-04-13","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-22-046451","document":"tm2212851-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922046451/tm2212851-6_4seq1.xml","form_type":"4"}},{"id":2296619,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51851,"kind":"person","name":"Odysseas Kostas D","position":1,"cik":"0001483080","reported_name":"Odysseas Kostas D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-15T19:52:00.000Z","date":"2022-04-13","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":33000,"derivative":{"exercise_price":5.11,"expiration_date":"2032-04-13","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-22-046449","document":"tm2212851-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922046449/tm2212851-5_4seq1.xml","form_type":"4"}},{"id":2296618,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61587,"kind":"person","name":"PATTI JOSEPH M","position":1,"cik":"0001283215","reported_name":"PATTI JOSEPH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-15T19:50:29.000Z","date":"2022-04-13","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":33000,"derivative":{"exercise_price":5.11,"expiration_date":"2032-04-13","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-22-046446","document":"tm2212851-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922046446/tm2212851-4_4seq1.xml","form_type":"4"}},{"id":2296616,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49454,"kind":"person","name":"Haimovitz Jules","position":1,"cik":"0001340855","reported_name":"Haimovitz Jules","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-15T19:49:15.000Z","date":"2022-04-13","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":33000,"derivative":{"exercise_price":5.11,"expiration_date":"2032-04-13","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-22-046444","document":"tm2212851-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922046444/tm2212851-3_4seq1.xml","form_type":"4"}},{"id":2296617,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128026,"kind":"person","name":"Morris Duane Alfred","position":1,"cik":"0001774205","reported_name":"Morris Duane Alfred","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-15T19:48:10.000Z","date":"2022-04-13","kind":"grant","acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant."}],"balance_after":41000,"derivative":{"exercise_price":5.11,"expiration_date":"2032-04-13","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001104659-22-046442","document":"tm2212851-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922046442/tm2212851-2_4seq1.xml","form_type":"4"}},{"id":2296615,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128024,"kind":"person","name":"Varnum Brian","position":1,"cik":"0001774252","reported_name":"Varnum Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-04-15T19:46:48.000Z","date":"2022-04-13","kind":"grant","acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant."}],"balance_after":240000,"derivative":{"exercise_price":5.11,"expiration_date":"2032-04-13","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001104659-22-046440","document":"tm2212851-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922046440/tm2212851-1_4seq1.xml","form_type":"4"}},{"id":2311824,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-04-01T20:52:45.000Z","date":"2022-03-31","kind":"purchase","acquired":true,"shares":0,"price":5,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"See Exhibit 99.1"},{"field":"security","element":"securityTitle","label":"F2","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":2692604,"derivative":{"exercise_price":5,"exercise_date":"2022-03-31","expiration_date":"2027-03-31","underlying":"Common Stock","underlying_shares":2692604},"source":{"system":"sec-edgar","filing":"0001567619-22-007861","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761922007861/doc1.xml","form_type":"4"}},{"id":2311823,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T20:52:45.000Z","date":"2022-03-31","kind":"purchase","acquired":true,"shares":5385208,"price":5,"value":26926040.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":16365969,"source":{"system":"sec-edgar","filing":"0001567619-22-007861","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761922007861/doc1.xml","form_type":"4"}},{"id":2402608,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-02-11T23:56:05.000Z","date":"2022-02-09","kind":"purchase","acquired":true,"shares":1807396,"price":5,"value":9036980.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"See Exhibit 99.1"},{"field":"security","element":"securityTitle","label":"F2","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":1807396,"derivative":{"exercise_price":5,"exercise_date":"2022-02-09","expiration_date":"2027-02-09","underlying":"Common Stock","underlying_shares":1807396},"source":{"system":"sec-edgar","filing":"0001567619-22-003750","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761922003750/doc1.xml","form_type":"4"}},{"id":2402607,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-11T23:56:05.000Z","date":"2022-02-09","kind":"purchase","acquired":true,"shares":3614792,"price":5,"value":18073960.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1"}],"balance_after":10980761,"source":{"system":"sec-edgar","filing":"0001567619-22-003750","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761922003750/doc1.xml","form_type":"4"}},{"id":2531093,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-01T18:20:02.000Z","date":"2021-10-29","kind":"purchase","acquired":true,"shares":1212122,"price":3.3,"value":4000002.6,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On October 28, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and another purchaser, pursuant to which, on October 29, 2021 Innoviva Sub acquired 1,212,122 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\").  In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of an additional 6,153,847 shares of Common Stock and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and in 2021, Innoviva designated Jules Haimovitz, two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, as a result of or in connection with the transactions reported on this Form 4."}],"balance_after":7365969,"source":{"system":"sec-edgar","filing":"0001567619-21-019063","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761921019063/doc1.xml","form_type":"4"}},{"id":2618706,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128024,"kind":"person","name":"Varnum Brian","position":1,"cik":"0001774252","reported_name":"Varnum Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-03T21:23:56.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant."}],"balance_after":125000,"derivative":{"exercise_price":3.82,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001104659-21-099565","document":"tm2124032-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921099565/tm2124032-2_4seq1.xml","form_type":"4"}},{"id":2676437,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49455,"kind":"person","name":"Schlesinger Sarah J.","position":1,"cik":"0001579873","reported_name":"Schlesinger Sarah J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-09T20:26:39.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":28000,"derivative":{"exercise_price":4.29,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001104659-21-078789","document":"tm2119245-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921078789/tm2119245-5_4seq1.xml","form_type":"4"}},{"id":2676436,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61585,"kind":"person","name":"Peterson Todd C.","position":1,"cik":"0001791061","reported_name":"Peterson Todd C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-09T20:26:19.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":28000,"derivative":{"exercise_price":4.29,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001104659-21-078788","document":"tm2119245-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921078788/tm2119245-4_4seq1.xml","form_type":"4"}},{"id":2676435,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61587,"kind":"person","name":"PATTI JOSEPH M","position":1,"cik":"0001283215","reported_name":"PATTI JOSEPH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-09T20:26:17.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":28000,"derivative":{"exercise_price":4.29,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001104659-21-078787","document":"tm2119245-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921078787/tm2119245-3_4seq1.xml","form_type":"4"}},{"id":2676434,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61588,"kind":"person","name":"Kramer Robin","position":1,"cik":"0001609222","reported_name":"Kramer Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-09T20:25:47.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":28000,"derivative":{"exercise_price":4.29,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001104659-21-078786","document":"tm2119245-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921078786/tm2119245-2_4seq1.xml","form_type":"4"}},{"id":2676433,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51851,"kind":"person","name":"Odysseas Kostas D","position":1,"cik":"0001483080","reported_name":"Odysseas Kostas D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-09T20:25:16.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":28000,"derivative":{"exercise_price":4.29,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001104659-21-078785","document":"tm2119245-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921078785/tm2119245-1_4seq1.xml","form_type":"4"}},{"id":2759117,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49454,"kind":"person","name":"Haimovitz Jules","position":1,"cik":"0001340855","reported_name":"Haimovitz Jules","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-06T01:46:01.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":4.74,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-21-046749","document":"tm2112142-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921046749/tm2112142-3_4seq1.xml","form_type":"4"}},{"id":2771090,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128024,"kind":"person","name":"Varnum Brian","position":1,"cik":"0001774252","reported_name":"Varnum Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CDO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-26T23:35:19.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":112000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant."}],"balance_after":112000,"derivative":{"exercise_price":5.14,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":112000},"source":{"system":"sec-edgar","filing":"0001104659-21-042631","document":"tm2111079-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921042631/tm2111079-4_4seq1.xml","form_type":"4"}},{"id":2771089,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128027,"kind":"person","name":"Patrick Todd","position":1,"cik":"0001762285","reported_name":"Patrick Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-26T23:35:03.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":112000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant."}],"balance_after":112000,"derivative":{"exercise_price":5.14,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":112000},"source":{"system":"sec-edgar","filing":"0001104659-21-042630","document":"tm2111079-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921042630/tm2111079-3_4seq1.xml","form_type":"4"}},{"id":2771088,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128026,"kind":"person","name":"Morris Duane Alfred","position":1,"cik":"0001774205","reported_name":"Morris Duane Alfred","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-26T23:34:48.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant."}],"balance_after":28000,"derivative":{"exercise_price":5.14,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001104659-21-042629","document":"tm2111079-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921042629/tm2111079-2_4seq1.xml","form_type":"4"}},{"id":2771087,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":125830,"kind":"person","name":"Martin Steven Robert","position":1,"cik":"0001328822","reported_name":"Martin Steven Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-26T23:33:55.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant."}],"balance_after":56000,"derivative":{"exercise_price":5.14,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001104659-21-042628","document":"tm2111079-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921042628/tm2111079-1_4seq1.xml","form_type":"4"}},{"id":2783982,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2021-03-17T21:16:08.000Z","date":"2021-03-17","kind":"purchase","acquired":true,"shares":4285935,"price":3.25,"value":13929288.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"See Ex. 99.1."},{"field":"security","element":"securityTitle","label":"F2","text":"See Ex. 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Ex. 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Ex. 99.1."}],"balance_after":6153847,"derivative":{"exercise_price":3.25,"exercise_date":"2021-03-17","expiration_date":"2026-03-17","underlying":"Common Stock","underlying_shares":4285935},"source":{"system":"sec-edgar","filing":"0001567619-21-006518","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761921006518/doc1.xml","form_type":"4"}},{"id":2783981,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-17T21:16:08.000Z","date":"2021-03-17","kind":"purchase","acquired":true,"shares":4285935,"price":3.25,"value":13929288.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"See Ex. 99.1."},{"field":"security","element":"securityTitle","label":"F2","text":"See Ex. 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Ex. 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Ex. 99.1."}],"balance_after":6153847,"source":{"system":"sec-edgar","filing":"0001567619-21-006518","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761921006518/doc1.xml","form_type":"4"}},{"id":2892591,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2021-01-28T18:43:45.000Z","date":"2021-01-26","kind":"purchase","acquired":true,"shares":1867912,"price":3.25,"value":6070714.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 26, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and acquired 1,867,912 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\") and warrants (\"Warrants\") to purchase 1,867,912 shares of Common Stock, with an exercise price per share of $3.25.  In addition, pursuant to transactions occurring in 2020, Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"security","element":"securityTitle","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization.  For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, including any shares of Common Stock underlying the Warrants, as a result of or in connection with the transactions reported in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On January 26, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and acquired 1,867,912 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\") and warrants (\"Warrants\") to purchase 1,867,912 shares of Common Stock, with an exercise price per share of $3.25.  In addition, pursuant to transactions occurring in 2020, Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization.  For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, including any shares of Common Stock underlying the Warrants, as a result of or in connection with the transactions reported in this Form 4."}],"balance_after":1867912,"derivative":{"exercise_price":3.25,"exercise_date":"2021-01-26","expiration_date":"2026-01-26","underlying":"Common Stock","underlying_shares":1867912},"source":{"system":"sec-edgar","filing":"0000899243-21-003595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921114/000089924321003595/doc4.xml","form_type":"4"}},{"id":2892590,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120750,"kind":"person","name":"Innoviva Strategic Opportunities LLC","position":2,"cik":"0001842875","reported_name":"Innoviva Strategic Opportunities LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-28T18:43:45.000Z","date":"2021-01-26","kind":"purchase","acquired":true,"shares":1867912,"price":3.25,"value":6070714.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 26, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and acquired 1,867,912 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\") and warrants (\"Warrants\") to purchase 1,867,912 shares of Common Stock, with an exercise price per share of $3.25.  In addition, pursuant to transactions occurring in 2020, Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"security","element":"securityTitle","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization.  For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, including any shares of Common Stock underlying the Warrants, as a result of or in connection with the transactions reported in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On January 26, 2021, Innoviva Strategic Opportunities LLC (\"Innoviva Sub\"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. (\"Innoviva\" and, together with Innoviva Sub, the \"Reporting Persons\"), entered into that certain Securities Purchase Agreement (the \"Purchase Agreement\") with Armata Pharmaceuticals, Inc., a Washington corporation (the \"Issuer\") and acquired 1,867,912 newly issued shares of common stock, $0.01 par value per share, of the Issuer (\"Common Stock\") and warrants (\"Warrants\") to purchase 1,867,912 shares of Common Stock, with an exercise price per share of $3.25.  In addition, pursuant to transactions occurring in 2020, Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock and 8,710,800 warrants to purchase Common Stock with an exercise price of $2.87."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In 2020, Innoviva designated Odysseas Kostas, M.D. and Sarah Schlesinger, M.D., two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization.  For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, including any shares of Common Stock underlying the Warrants, as a result of or in connection with the transactions reported in this Form 4."}],"balance_after":1867912,"source":{"system":"sec-edgar","filing":"0000899243-21-003595","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000089924321003595/doc4.xml","form_type":"4"}},{"id":2952423,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128027,"kind":"person","name":"Patrick Todd","position":1,"cik":"0001762285","reported_name":"Patrick Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:11:49.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001104659-20-133644","document":"tm2038059-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133644/tm2038059-11_4seq1.xml","form_type":"4"}},{"id":2952422,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61587,"kind":"person","name":"PATTI JOSEPH M","position":1,"cik":"0001283215","reported_name":"PATTI JOSEPH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:11:27.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001104659-20-133643","document":"tm2038059-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133643/tm2038059-10_4seq1.xml","form_type":"4"}},{"id":2952421,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61585,"kind":"person","name":"Peterson Todd C.","position":1,"cik":"0001791061","reported_name":"Peterson Todd C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:11:05.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001104659-20-133642","document":"tm2038059-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133642/tm2038059-9_4seq1.xml","form_type":"4"}},{"id":2952420,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128026,"kind":"person","name":"Morris Duane Alfred","position":1,"cik":"0001774205","reported_name":"Morris Duane Alfred","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:10:40.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001104659-20-133641","document":"tm2038059-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133641/tm2038059-8_4seq1.xml","form_type":"4"}},{"id":2952419,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61588,"kind":"person","name":"Kramer Robin","position":1,"cik":"0001609222","reported_name":"Kramer Robin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:08:45.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-20-133639","document":"tm2038059-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133639/tm2038059-7_4seq1.xml","form_type":"4"}},{"id":2952418,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":125830,"kind":"person","name":"Martin Steven Robert","position":1,"cik":"0001328822","reported_name":"Martin Steven Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:08:16.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001104659-20-133638","document":"tm2038059-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133638/tm2038059-6_4seq1.xml","form_type":"4"}},{"id":2952417,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49455,"kind":"person","name":"Schlesinger Sarah J.","position":1,"cik":"0001579873","reported_name":"Schlesinger Sarah J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:07:53.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001104659-20-133637","document":"tm2038059-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133637/tm2038059-5_4seq1.xml","form_type":"4"}},{"id":2952416,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128024,"kind":"person","name":"Varnum Brian","position":1,"cik":"0001774252","reported_name":"Varnum Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CDO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:06:29.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001104659-20-133633","document":"tm2038059-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133633/tm2038059-4_4seq1.xml","form_type":"4"}},{"id":2952415,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":144804,"kind":"person","name":"BASTIANI RICHARD","position":1,"cik":"0001202053","reported_name":"BASTIANI RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:06:09.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001104659-20-133631","document":"tm2038059-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133631/tm2038059-3_4seq1.xml","form_type":"4"}},{"id":2952414,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51851,"kind":"person","name":"Odysseas Kostas D","position":1,"cik":"0001483080","reported_name":"Odysseas Kostas D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-09T21:05:47.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":3.15,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001104659-20-133628","document":"tm2038059-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920133628/tm2038059-2_4seq1.xml","form_type":"4"}},{"id":3191509,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Acquire Common Stock","published_at":"2020-03-31T20:54:01.000Z","date":"2020-03-27","kind":"purchase","acquired":true,"shares":7717661,"price":2.87,"value":22149687.07,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"See Exhibit 99.1."}],"balance_after":8710800,"derivative":{"exercise_price":2.87,"exercise_date":"2020-03-27","expiration_date":"2025-03-27","underlying":"Common Stock","underlying_shares":7717661},"source":{"system":"sec-edgar","filing":"0001567619-20-007226","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761920007226/doc1.xml","form_type":"4"}},{"id":3191508,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":4679,"kind":"organization","name":"Innoviva, Inc.","position":1,"cik":"0001080014","reported_name":"Innoviva, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-31T20:54:01.000Z","date":"2020-03-27","kind":"purchase","acquired":true,"shares":7717661,"price":2.87,"value":22149687.07,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"See Exhibit 99.1."}],"balance_after":8710800,"source":{"system":"sec-edgar","filing":"0001567619-20-007226","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000156761920007226/doc1.xml","form_type":"4"}},{"id":3271843,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":51851,"kind":"person","name":"Odysseas Kostas D","position":1,"cik":"0001483080","reported_name":"Odysseas Kostas D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-15T00:39:16.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":27383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant."}],"balance_after":27383,"derivative":{"exercise_price":4.17,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":27383},"source":{"system":"sec-edgar","filing":"0001104659-20-022126","document":"tm208184-4_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920022126/tm208184-4_form4.xml","form_type":"4"}},{"id":3271842,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":49455,"kind":"person","name":"Schlesinger Sarah J.","position":1,"cik":"0001579873","reported_name":"Schlesinger Sarah J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-14T23:04:14.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":27383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant."}],"balance_after":27383,"derivative":{"exercise_price":4.17,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":27383},"source":{"system":"sec-edgar","filing":"0001104659-20-022097","document":"tm208184-3_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920022097/tm208184-3_form4.xml","form_type":"4"}},{"id":3271841,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":41275,"kind":"person","name":"COOK JEREMY CURNOCK","position":1,"cik":"0001216486","reported_name":"COOK JEREMY CURNOCK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2020-02-14T23:00:35.000Z","date":"2019-05-09","kind":"other","acquired":false,"shares":46666,"price":12065.46,"value":563046756.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Price reported is reflective of adjustments made after the date of issuance pursuant the terms of the warrant."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were redeemed by the issuer for $12,065.46."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The number of shares of common stock for which the warrant was exercisable does not reflect the 1-for-14 reverse stock split that was effected on May 9, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The warrant was held by One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II (\"One Funds Management\"). The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":0.3223,"exercise_date":"2016-11-22","expiration_date":"2021-11-22","underlying":"Common Stock","underlying_shares":46666},"source":{"system":"sec-edgar","filing":"0001104659-20-022092","document":"tm208184-5_form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920022092/tm208184-5_form5.xml","form_type":"5"}},{"id":3271840,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":21398,"kind":"person","name":"PERRY MICHAEL S","position":1,"cik":"0001250379","reported_name":"PERRY MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2020-02-14T22:58:19.000Z","date":"2019-05-09","kind":"other","acquired":false,"shares":46666,"price":12065.46,"value":563046756.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Price reported is reflective of adjustments made to the exercise price after the date of issuance pursuant to the terms of the warrant."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were redeemed by the issuer for $12,065.46."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The number of shares of common stock for which the warrant was exercisable does not reflect the 1-for-14 reverse stock split that was effected on May 9, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The warrant was held by One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II (\"One Funds Management\"). The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":0.3223,"exercise_date":"2016-11-22","expiration_date":"2021-11-22","underlying":"Common Stock","underlying_shares":46666},"source":{"system":"sec-edgar","filing":"0001104659-20-022091","document":"tm208184-6_form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465920022091/tm208184-6_form5.xml","form_type":"5"}},{"id":3393908,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61585,"kind":"person","name":"Peterson Todd C.","position":1,"cik":"0001791061","reported_name":"Peterson Todd C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-15T20:06:07.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":27383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant."}],"balance_after":27383,"derivative":{"exercise_price":3.77,"expiration_date":"2029-10-10","underlying":"Common Stock","underlying_shares":27383},"source":{"system":"sec-edgar","filing":"0001104659-19-054141","document":"tv531072_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465919054141/tv531072_4.xml","form_type":"4"}},{"id":3512672,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":128024,"kind":"person","name":"Varnum Brian","position":1,"cik":"0001774252","reported_name":"Varnum Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CDO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-25T01:30:32.000Z","date":"2019-05-22","kind":"grant","acquired":true,"shares":298724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each annual anniversary of the date of grant."}],"balance_after":298724,"derivative":{"exercise_price":3.15,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":298724},"source":{"system":"sec-edgar","filing":"0001144204-19-028255","document":"tv522361_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000114420419028255/tv522361_4.xml","form_type":"4"}}],"next_cursor":"2019-05-25T01:30:32.000000Z,3512672"}